Abstract
We reviewed Food and Drug Administration postmarketing reports of central nervous system (CNS) anticholinergic effects in association with oxybutynin. Taking domestic usage by age group into account, there is a disproportionately higher number of CNS adverse event cases reported in pediatric patients as compared with adult patients. CNS stimulation was prominent in the pediatric cases.
MeSH terms
-
Adolescent
-
Adult
-
Adverse Drug Reaction Reporting Systems / statistics & numerical data*
-
Age Factors
-
Central Nervous System / drug effects
-
Child
-
Child, Preschool
-
Databases as Topic
-
Humans
-
Infant
-
Mandelic Acids / administration & dosage
-
Mandelic Acids / adverse effects*
-
Middle Aged
-
Muscarinic Antagonists / administration & dosage
-
Muscarinic Antagonists / adverse effects*
-
Nervous System Diseases / chemically induced*
-
Nocturnal Enuresis / drug therapy
-
Young Adult
Substances
-
Mandelic Acids
-
Muscarinic Antagonists
-
oxybutynin